These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16763096)

  • 1. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model.
    Dvir E; Friedman JE; Lee JY; Koh JY; Younis F; Raz S; Shapiro I; Hoffman A; Dahan A; Rosenberg G; Angel I; Kozak A; Duvdevani R
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1248-56. PubMed ID: 16763096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy.
    Dvir E; Elman A; Simmons D; Shapiro I; Duvdevani R; Dahan A; Hoffman A; Friedman JE
    CNS Drug Rev; 2007; 13(2):260-77. PubMed ID: 17627676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx.
    Dahan A; Hoffman A
    Drug Metab Dispos; 2007 Feb; 35(2):321-4. PubMed ID: 17142563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate.
    Dahan A; Duvdevani R; Dvir E; Elmann A; Hoffman A
    J Control Release; 2007 May; 119(1):86-93. PubMed ID: 17382425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
    Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
    J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytopreventative effects of Gynostemma pentaphyllum against acute Indomethacin-induced gastrointestinal and renal toxicity in rats.
    Hesse C; Razmovski-Naumovski V; Duke CC; Davies NM; Roufogalis BD
    Phytother Res; 2007 Jun; 21(6):523-30. PubMed ID: 17380554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
    Stock N; Munoz B; Wrigley JD; Shearman MS; Beher D; Peachey J; Williamson TL; Bain G; Chen W; Jiang X; St-Jacques R; Prasit P
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2219-23. PubMed ID: 16455248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
    van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
    ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
    Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
    Lee JY; Kweon HS; Cho E; Lee JY; Byun HR; Kim DH; Kim YH; Han PL; Koh JY
    Neurosci Lett; 2007 Aug; 423(1):82-7. PubMed ID: 17662525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
    Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
    Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.